[go: up one dir, main page]

WO1995015331B1 - PROTEINES ET ACIDES NUCLEIQUES SPECIFIQUES FUSIONNES PRESENTS DANS LE LYMPHOME HUMAIN t(2;5), ET LEURS METHODES DE DETECTION ET D'UTILISATION - Google Patents

PROTEINES ET ACIDES NUCLEIQUES SPECIFIQUES FUSIONNES PRESENTS DANS LE LYMPHOME HUMAIN t(2;5), ET LEURS METHODES DE DETECTION ET D'UTILISATION

Info

Publication number
WO1995015331B1
WO1995015331B1 PCT/US1994/013947 US9413947W WO9515331B1 WO 1995015331 B1 WO1995015331 B1 WO 1995015331B1 US 9413947 W US9413947 W US 9413947W WO 9515331 B1 WO9515331 B1 WO 9515331B1
Authority
WO
WIPO (PCT)
Prior art keywords
alk
agent
protein
lymphoma
npm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/013947
Other languages
English (en)
Other versions
WO1995015331A1 (fr
Filing date
Publication date
Priority claimed from US08/160,861 external-priority patent/US5529925A/en
Application filed filed Critical
Priority to AU15116/95A priority Critical patent/AU679833B2/en
Priority to DE69433665T priority patent/DE69433665T3/de
Priority to JP7515804A priority patent/JPH09512161A/ja
Priority to EP95906601A priority patent/EP0731806B2/fr
Publication of WO1995015331A1 publication Critical patent/WO1995015331A1/fr
Publication of WO1995015331B1 publication Critical patent/WO1995015331B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

L'invention porte sur l'identification, et la détermination des séquences, de protéines fusionnées produites par translocation et présentes dans les cellules des lymphomes t(2;5). L'invention fournit des méthodes de détection et de traitement du lymphome t(2;5) utilisant les séquences susdites d'acides aminés ou d'acide nucléique de ces protéines fusionnées.
PCT/US1994/013947 1993-12-03 1994-12-05 PROTEINES ET ACIDES NUCLEIQUES SPECIFIQUES FUSIONNES PRESENTS DANS LE LYMPHOME HUMAIN t(2;5), ET LEURS METHODES DE DETECTION ET D'UTILISATION Ceased WO1995015331A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU15116/95A AU679833B2 (en) 1993-12-03 1994-12-05 Specific fusion nucleic acids and proteins present in human t(2;5) lymphoma, methods of detection and uses thereof
DE69433665T DE69433665T3 (de) 1993-12-03 1994-12-05 SPEZIFISCHE FUSIONSNUKLEINSÄUREN UND PROTEINE IN HUMANEN t(2;5)LYMPHOMEN, VERFAHREN ZU IHREM NACHWEIS UND IHRE VERWENDUNG
JP7515804A JPH09512161A (ja) 1993-12-03 1994-12-05 ヒトｔ（２；５）リンパ腫に存在する特異的融合核酸及びタンパク質、それらの検出方法及び用途
EP95906601A EP0731806B2 (fr) 1993-12-03 1994-12-05 PROTEINES ET ACIDES NUCLEIQUES SPECIFIQUES FUSIONNES PRESENTS DANS LE LYMPHOME HUMAIN t(2;5), ET LEURS METHODES DE DETECTION ET D'UTILISATION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/160,861 US5529925A (en) 1993-12-03 1993-12-03 Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US08/160,861 1993-12-03

Publications (2)

Publication Number Publication Date
WO1995015331A1 WO1995015331A1 (fr) 1995-06-08
WO1995015331B1 true WO1995015331B1 (fr) 1995-06-22

Family

ID=22578775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/013947 Ceased WO1995015331A1 (fr) 1993-12-03 1994-12-05 PROTEINES ET ACIDES NUCLEIQUES SPECIFIQUES FUSIONNES PRESENTS DANS LE LYMPHOME HUMAIN t(2;5), ET LEURS METHODES DE DETECTION ET D'UTILISATION

Country Status (7)

Country Link
US (4) US5529925A (fr)
EP (1) EP0731806B2 (fr)
JP (1) JPH09512161A (fr)
AU (1) AU679833B2 (fr)
CA (1) CA2177957A1 (fr)
DE (1) DE69433665T3 (fr)
WO (1) WO1995015331A1 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696548B2 (en) 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US5635351A (en) * 1995-03-14 1997-06-03 The Regents Of The University Of California Genetic gain and loss in gliomas
US20030165931A1 (en) * 1998-03-11 2003-09-04 Bruno Tocque Qualitative differential screening
US6881571B1 (en) 1998-03-11 2005-04-19 Exonhit Therapeutics S.A. Qualitative differential screening
DE19610255B4 (de) * 1996-03-15 2004-11-04 Universität Heidelberg Verfahren zur Herstellung von Nukleinsäuresequenzen und Verfahren zum Nachweis von Translokationen zwischen Chromosomen
US8048629B2 (en) * 1996-03-15 2011-11-01 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
JP2001505428A (ja) * 1996-12-06 2001-04-24 ニールズ パリスガード 染色体異常の検出
US5994522A (en) * 1997-01-24 1999-11-30 Washington University BLNK proteins
US20030096255A1 (en) * 1997-02-19 2003-05-22 Felix Carolyn A. Methods and kits for analysis of chromosomal rearrangements associated with cancer
EP0878552A1 (fr) * 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Détection moléculaire d'aberration chromosomique
US6849400B1 (en) * 1997-07-23 2005-02-01 Gen-Probe Incorporated Methods for detecting and measuring spliced nucleic acids
EP1078098A1 (fr) 1998-05-04 2001-02-28 Dako A/S Procede et sondes de detection d'aberrations chromosomiques
FR2798392B1 (fr) * 1999-09-13 2005-07-15 Exonhit Therapeutics Sa Marqueurs genetiques de la toxicite, preparation et utilisations
FR2798673B1 (fr) * 1999-09-16 2004-05-28 Exonhit Therapeutics Sa Methodes et compositions pour la detection d'evenements pathologiques
ATE460427T1 (de) * 2000-06-14 2010-03-15 Univ Georgetown Pleiotrophin wachstumfaktor rezeptor alk zur behandlung von proliferativen, gefässer- und neurologischen erkrankungen
WO2002088309A2 (fr) * 2001-04-27 2002-11-07 St. Jude Children's Research Hospital Genes de fusion associes aux leucemies aigues megacaryoblastiques
US7214488B2 (en) * 2001-07-03 2007-05-08 United States Of America, Represented By The Secretary, Department Of Health And Human Services Detection of MECT1-MAML2 fusion products
US20030157101A1 (en) * 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides
US8623822B2 (en) * 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
WO2004065621A1 (fr) 2002-03-01 2004-08-05 Dyax Corp. Peptides de liaison kdr et vegf/kdr et leur utilisation a des fins diagnostiques et therapeutiques
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7461843B1 (en) * 2002-08-23 2008-12-09 Elixir Gaming Technologies, Inc. Automatic card shuffler
US7413851B2 (en) * 2002-12-13 2008-08-19 Aurelium Biopharma, Inc. Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
ATE328112T1 (de) * 2003-03-07 2006-06-15 Ist Naz Stud Cura Dei Tumori Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon
US7888485B2 (en) * 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
ITRM20040534A1 (it) * 2004-10-29 2005-01-29 Brunangelo Falini Mutanti della proteina nucleofosmina (npm), sequenze geniche corrispondenti e relativi usi.
DE212006000071U1 (de) 2005-11-18 2008-07-24 Board of Regents, The University of Texas System, Austin Quantifizierung von Fusionsproteinen und ihrer Aktivität in Folge chromosomaler Translokation
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
AU2012201154B2 (en) * 2006-04-14 2012-09-13 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
DK2016089T3 (da) * 2006-04-14 2014-04-22 Cell Signaling Technology Inc Gendefekter og mutant-alk-kinase i humane faste tumorer
EP2447360A1 (fr) * 2006-04-14 2012-05-02 Cell Signaling Technology, Inc. Défauts de gène et ALK kinase mutante dans des tumeurs solides humaines
CN101443361B (zh) 2006-04-28 2015-08-19 德勒尼克斯治疗股份公司 与受体酪氨酸激酶alk的胞外域结合的抗体
WO2009045965A2 (fr) * 2007-10-01 2009-04-09 The Trustees Of The University Of Pennsylvania Stat5a et ses analogues fonctionnels suppresseurs de tumeur pour le traitement de tumeurs malignes exprimant npm/alk et d'autres kinases oncogènes
AU2009215168A1 (en) * 2008-02-12 2009-08-20 Dana-Farber Cancer Institute Fish assay for EML4 and ALK fusion in lung cancer
US8352194B1 (en) 2008-06-17 2013-01-08 University Of South Florida Method to identify cancer fusion genes
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
EP3360978A3 (fr) 2009-05-07 2018-09-26 Veracyte, Inc. Procédés pour le diagnostic d'affections thyroïdiennes
EP2432900A4 (fr) * 2009-05-15 2012-11-21 Insight Genetics Inc Méthodes et compositions associés à des fusions de la kinase alk pour diagnostiquer et traiter le cancer
EP3546596B1 (fr) 2009-05-26 2022-05-11 Quest Diagnostics Investments Incorporated Utilisation d'une trousse pour la détection de dysfonctionnements géniques
EP2487250A4 (fr) * 2009-10-06 2013-03-20 Fujirebio Kk Procédé de détection d'un gène de fusion
JP2013510585A (ja) * 2009-11-13 2013-03-28 インフィニティー ファーマシューティカルズ， インコーポレイテッド 癌の同定、評価、予防および治療のための組成物、キットおよび方法
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
WO2011079191A1 (fr) 2009-12-23 2011-06-30 Quest Diagnostics Investments Incorporated Utilisation de tmprss2 dans le diagnostic d'une maladie de la prostate
CA2936532A1 (fr) * 2010-04-20 2011-10-27 Ventana Medical Systems, Inc. Hybridation in situ chromogene a deux couleurs
AU2015201135B2 (en) * 2010-04-20 2017-02-02 Ventana Medical Systems, Inc. Two-color chromogenic in situ hybridization
WO2012019132A2 (fr) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Kinase des lymphomes anaplasiques dans le cancer du rein
EP2714038A1 (fr) 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Thérapie combinée par des composés inhibiteurs de hsp90 et des inhibiteurs de mtor/pi3k
WO2013006864A2 (fr) 2011-07-07 2013-01-10 Synta Pharmaceuticals Corp. Traitement du cancer au moyen de composés inhibiteurs de hsp90
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
EP2780010A1 (fr) 2011-11-14 2014-09-24 Synta Pharmaceuticals Corp. Association thérapeutique d'inhibiteurs de hsp90 et d'inhibiteurs de braf
PL2838998T3 (pl) 2012-04-18 2018-04-30 Cell Signaling Technology, Inc. EGFR i ROS1 w nowotworze
WO2013170182A1 (fr) 2012-05-11 2013-11-14 Synta Pharmaceuticals Corp. Traitement d'un cancer au moyen d'un composé inhibiteur de hsp90
HK1211235A1 (en) 2013-02-22 2016-05-20 霍夫曼-拉罗奇有限公司 Methods of treating cancer and preventing drug resistance
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US9284594B2 (en) * 2013-07-23 2016-03-15 The Regents Of The University Of Michigan Compositions and methods relating to fusion protein biomarkers
US10160993B2 (en) * 2014-03-21 2018-12-25 Purdue Research Foundation Tyrosine kinase biosensors and methods of use
CN115354076A (zh) * 2014-03-25 2022-11-18 奎斯特诊断投资股份有限公司 通过使用平均循环阈值的基因内差异表达(ide)检测基因融合
FI3143026T3 (fi) 2014-05-13 2024-10-10 Novartis Ag Yhdisteitä ja koostumuksia kondrogeneesin indusoimiseksi
US10246750B2 (en) * 2014-06-10 2019-04-02 Blueprint Medicines Corporation Method for detection of a TECR:PKN1 or an ANXA4:PKN1 gene fusion
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
JP7356788B2 (ja) 2014-11-05 2023-10-05 ベラサイト インコーポレイテッド 機械学習および高次元転写データを使用して経気管支生検における特発性肺線維症を診断するシステムおよび方法
CN107645957A (zh) 2015-02-09 2018-01-30 辛塔制药公司 治疗癌症的hsp90抑制剂和pd‑1抑制剂的组合疗法
GB2557818A (en) * 2015-09-25 2018-06-27 Veracyte Inc Methods and compositions that utilize transciptome sequencing data in machine learning-based classification
CA3268717A1 (fr) * 2016-12-09 2025-11-29 Ncan Genomics, Inc. Ligature liée
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
AU630001B2 (en) * 1989-10-02 1992-10-15 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A sensitive method for measurement of chimeric transcripts of dna containing translocations
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma

Similar Documents

Publication Publication Date Title
WO1995015331B1 (fr) PROTEINES ET ACIDES NUCLEIQUES SPECIFIQUES FUSIONNES PRESENTS DANS LE LYMPHOME HUMAIN t(2;5), ET LEURS METHODES DE DETECTION ET D'UTILISATION
CA2286304A1 (fr) Pca3, genes de pca3, et procedes d'utilisation
WO1996039429A3 (fr) Proteine serique produite exclusivement dans les adipocytes
NL300119I1 (nl) Voor Factor VIIIC coderende DNA-sequenties en verwante DNA-contructen.
WO1998049313A3 (fr) Caracterisation d'erhlichia granulocyte et methodes d'utilisation
EP2048505A3 (fr) Procédé de reconnaissance précoce de la séroconversion d'un anticorps orienté contre le virus de l'hépatite C
AU2002223044A1 (en) Kit and method for detecting the esm-1 protein
CA2234416A1 (fr) Determination immunochimique d'analytes multivalents
WO1998057984A3 (fr) Torsine, genes de torsine et leurs utilisations
AU2126400A (en) Detection of small molecules by use of a piezoelectric sensor
ATE223491T1 (de) Verfahren zur reinigung von biomolekül- oder proteinkomplexen
CA2366523A1 (fr) Procede d'analyse de la quantite de tissu adipeux intra-abdominal
WO1995013386A3 (fr) Enzyme de fusion de la proteine activatrice de la tyrosinase
AU2256197A (en) High affinity nucleic acid ligands of complement system proteins
WO2003038116A3 (fr) Facteurs de virulence de salmonella et leurs utilisations
ZA200007619B (en) New peptide fragments for protein purification.
WO2002072753A3 (fr) Peptides de thymidylate synthase se fixant a l'arnm de la thymidylate synthase
WO1999023228B1 (fr) Polypeptides et adn svph1-26
Sokolovsky et al. Exhaustive Proteolysis of Derivatives of Lysozyme
EP1143011A3 (fr) Méthode pour detécter des substances biologiquement actives
WO1999050288A3 (fr) Gene mammalien kd312 induit par perte sanguine
AU4624997A (en) Nematode proteins, dna sequences coding therefor, their specific antibodies and their use in identifying nematicidal active substances
CA2588614A1 (fr) Procede d'analyse de la quantite de tissu adipeux intra-abdominal
WO2002016574A3 (fr) Procede d'identification de peptides de fission specifique et utilisation de telles sequences peptidiques